Natural phytoconstituents and herbal supplements: A potential therapeutic strategies against COVID infection

Ganesh Jayram Lamkhade *, Pratik Dilip Deshmukh, Suvir Ramesh Darekar, Anant Shankar More and Amir Afzal Shaikh

Department of Pharmaceutics Indira College of Pharmacy, Tathwade, Pune 411033, Maharashtra, India.
 
Review
World Journal of Biology Pharmacy and Health Sciences, 2023, 13(01), 028-038.
Article DOI: 10.30574/wjbphs.2023.13.1.0282
Publication history: 
Received on 16 November 2022; revised on 30 December 2022; accepted on 01 January 2023
 
Abstract: 
The SARS-cov-2 virus was initially identified in Wuhan in November 2019, and later spread globally sparking the present pandemic. Since there are currently no specified cures for COVID-19, researchers have the chance to develop alternative drugs or vaccines, thus numerous synthetic bioactive molecules are now being explored in clinical studies. The broad therapeutic scope and negligible health consequences, traditional medicines have been utilized for a relatively long time in various clinical emergencies. Considering there weren't enough synthetic antiviral medications available, pharmaceutical and alternative therapies have been established using a number of plant constituents. 85% of the immune system is made up of good gut bacteria, which were enhanced by plant-based meals. People routinely utilize a wide variety of natural plants and herbs to cure several categories of disorders owing to the wide access of herbal and nutritional products globally. This article illustrates how earlier studies have demonstrated that several plants have immunomodulatory and antiviral properties, as well as role of their active constituents in order to build immunity against COVID-19. Despite the availability of FDA approved therapies and vaccinations for the management of COVID-19, the goal is to promote the usage of natural supplements as immunotherapies and vaccine adjuvants.
 
Keywords: 
Natural Phytoconstituents; Herbal supplements; COVID treatment; SARS-cov- 2; Post-COVID syndrome; Targets for SARS-cov-2
 
Full text article in PDF: